文献速递白血病造血干细胞移植与细胞治疗

细胞遗传学风险评分在接受缓解期移植且可检测到可测量残留病的急性髓系白血病患者中保持预后意义:代表欧洲血液与骨髓移植学会急性白血病工作组

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation.
PubMed 文献 · Am J Hematol · 2020-07-09

该研究基于欧洲血液与骨髓移植学会急性白血病工作组数据,评估已发表的细胞遗传学预后模型在可测量残留病阳性(MRD+)的急性髓系白血病(AML)患者接受异基因造血干细胞移植(allo-SCT)中的预后价值。共纳入775例首次完全缓解、接受配型相合同胞供者或无关供者移植的MRD+患者,中位随访22个月。细胞遗传学风险评分可区分白血病无病生存和复发风险,是MRD+ AML患者风险分层的有效辅助工具。

要点

  • 在MRD+ AML移植患者中,细胞遗传学风险评分仍可区分预后:良好/中间型FLT3wt组2年无白血病生存率78%/61%,中间型FLT3-ITD3/不良组仅50%/37%(P<.001)。
  • 多因素分析显示,不良风险组和中间型FLT3-ITD3组较良好风险组复发风险更高(HR分别为3.9和4.4)。
  • 欧洲血液与骨髓移植学会细胞遗传学风险评分是MRD+ AML患者风险分层的有效辅助工具。

核心结论

  • 欧洲血液与骨髓移植学会细胞遗传学风险评分是MRD+急性髓系白血病患者风险分层的有效辅助工具。

研究设计与样本

  • 基于欧洲血液与骨髓移植学会急性白血病工作组数据,纳入775例首次完全缓解、接受配型相合同胞供者或无关供者异基因造血干细胞移植的MRD+急性髓系白血病患者,中位随访22个月。

主要发现

  • 细胞遗传学风险评分分布为:良好风险15%、中间型/FLT3wt 28.3%、中间型/FLT3-ITD3 37%、不良风险19.7%。
  • 良好风险和中间型/FLT3wt风险组2年白血病无病生存率分别为78%和61%,中间型/FLT3-ITD3和不良风险组分别为50%和37%(P<.001)。
  • 多因素分析中,不良风险组较良好风险组复发风险更高(HR=3.9,95%CI 2.1-7.3;P<.001),中间型/FLT3-ITD3组较良好风险组复发风险更高(HR=4.4,95%CI 2.4-7.8;P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+ patients in first complete remission undergoing allo-SCT from a matched sibling donor or unrelated donor. Seven hundred and seventy-five patients were evaluated with a median follow-up duration of 22 months. Cytogenetic risk score was favorable, intermediate/FLT3wt intermediate/FLT3-ITD3, and adverse in 15%, 28.3%, 37% and 19.7% of the patients, respectively. Favorable and intermediate/FLT3wt risk patients had 2-year leukemia-free survival rates of 78% and 61%, respectively, compared with only 50% and 37% for intermediate/FLT3-ITD3 and adverse risk patients, respectively (P < .001). In multivariate analysis adverse and intermediate/FLT3-ITD3 risk patients were more likely to experience disease relapse compared with favorable risk patients [hazard ratio (HR) = 3.9, 95% confidence interval (CI), 2.1-7.3; P < .001, and HR = 4.4, CI 95%, 2.4-7.8; P < .001, respectively]. The European society for blood and marrow transplantation cytogenetic risk score is a valuable adjunct for risk stratification of MRD+ AML patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nagler A, Labopin M, Canaani J, et al. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Am J Hematol. 2020. PMID: 32530520. doi:10.1002/ajh.25905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。